Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q2 FY2023 Earnings Presentation
25 slides from Morepen Laboratories's earnings presentation, Nov 10, 2022
Slide 1: Exchange filing cover letter: Investors Presentation Q2 FY23
. ..;.."'***..* KJJof>HJ Y(A 5 ♦ • 1 '1mEPEN Date: 10/11/2022 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investors P
Slide 2: Q2'FY23 Earnings Presentation - Nov 2022
MOREPEN LABORATORIES LIMITED Q2'FY23 earnings Presentation - Nov 2022
Slide 3: Disclaimer/ Confidentiality
Disclaimer/ Confidentiality This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied
Slide 4: Quarterly Highlights
CONSOLIDATED Shareholding pattern QUARTERLY HIGHLIGHTS Promoters • During the current Quarter Q2'FY23, the business has started stabilising post covid period, and is on the path to recovery. 38.2% Public • During quarter Q2'FY23, the company has achieved the 56.5% highest ever Quarterly Revenue of a
Slide 5: Consolidated quarterly performance
CONSOLIDATED quarterly performance
Slide 6: Revenue Growth
CONSOLIDATED REVENUE GROWTH 34% CAGR Rs. in crores 2,000 23% CAGR ^30% 1,500 1557 500 388.31 1200 400 1,000 398 404 863 300 340 up 87% from 707 pre-covid level 500 200 216 100 0 FY'20 FY'21 FY'22 H1'23 0 Q2'FY20 Q2'FY21 Q2'FY22 Q2'FY23 Annual performance Q2'FY23 performance JlOREPEN
Slide 7: Business Segments
CONSOLIDATED BUSINESS SEGMENTS API BUSINESS MEDICAL DEVICES FORMULATIONS OTC (SUBSIDIARY) . orepen®
Slide 8: Segments Wise Performance
CONSOLIDATED SEGMENTS WISE PERFORMANCE API DIAGNOSTICS FORMULATIONS DR.MOREPEN -OTC ^21% -23% ^2% -27% 250 125 50 30 200 243.36 100 122.59 200.99 40 28.18 41.47 42.44 150 75 94.11 20 30 20.61 100 50 20 10 50 25 10 0 0 Q2'FY22 Q2'FY23 Q2'FY22 Q2'FY23 0 0 Q2'FY22 Q2'FY23 Q2'FY22 Q2'FY23 NOTE: current
Slide 9: Segment Wise Breakup
STANDALONE SEGMENT WISE BREAKUP Formulations 13.7% share h1 FY'22 H1'FY23 API 6.80% f Diagnostic Devices 53.3% 60.1% 26.2% API 60.1% Diagnostics 8.90% 35.1% 26.2% revenue split H1'FY'23 formulations 2.10% f 11.6% 13.7% JlOREPEN
Slide 10: API Business
API BUSINESS leadership through quality
Slide 11: API Revenue
api business API REVENUE 35% CAGR Rs. in crores 1,000 ^26% 858 CAGR 28% 750 250 ^21% 683 243.36 500 200 200.99 474 184.62 up 109% from 389 150 pre-covid level 250 112.42 100 116.37 50 0 FY'20 FY'21 FY'22 H1'23 0 Q2'FY20 Q2'FY21 Q2'FY22 Q2'FY23 Annual performance Q2'FY23 performance
Slide 12: Key API Products
api business KEY API PRODUCTS LORATADINE MONTELUKAST ^44% -16% ATORVASTATIN NEW MOLECULES ^21% ^145% J\\OREPEN
Slide 13: POC Medical Devices
---- ~ • -----... - --- / ' ~N \ I I I I \ I I I ..... POC MEDICAL DEVICES market leadership ,,_. .---- < ) r ) ., .,....,,,, _., l_..... • ,.., \
Slide 14: POC Revenue
POC medical devices POC REVENUE 58% CAGR Rs. in crores 500 400 ^46% CAGR 27% 419 125 122.59 300 100 287 94.11 90.36 200 75 up107% from 168 172 pre-covid level 100 50 45.52 25 0 FY'20 FY'21 FY'22 H1'23 0 Q2'FY20 Q2'FY21 Q2'FY22 Q2'FY23 Annual performance Q2'FY23 performance
Slide 15: Gluco Meter Revenue
POC medical devices GLUCO METER REVENUE 52% CAGR Rs. in crores 300 ^55% 279 CAGR 30% 200 100 180 75 84.72 137 74.00 100 120 50 58.27 up 121% from pre-covid level 25 33.52 0 FY'20 FY'21 FY'22 H1'23 0 Annual performance Q2'FY20 Q2'FY21 Q2'FY22 Q2'FY23 Q2'FY23 performance
Slide 16: BP Monitor Revenue
POC medical devices BP MONITOR REVENUE 70% CAGR Rs. in crores 100 ^33% 75 84 CAGR 32% 30 63 28.87 50 20 20.03 25 29 29 16.14 121% growth from 10 pre-covid level 0 7.03 FY'20 FY'21 FY'22 H1'23 0 Q2'FY20 Q2'FY21 Q2'FY22 Q2'FY23 Annual performance Q2'FY23 performance
Slide 17: Formulations
FORMULATIONS brandeD formulations in india
Slide 18: Formulations Revenue
FORMULATIONS FORMULATIONS REVENUE 11% CAGR Rs. in crores 200 ^29% 150 169 CAGR 9% 138 50 131 39.90 up 29% from 100 40 44.98 44.87 pre-covid level 90 30 34.70 35.17 50 20 10 0 FY'20 FY'21 FY'22 H1'23 0 Q2'FY20 Q2'FY21 Q2'FY22 Q2'FY23 Annual performance Q2'FY23 performance
Slide 19: Growth Drivers
FORMULATIONS GROWTH DRIVERS ^13% ^34% antibiotics vitamins -8% ^6% gastro others J\\OREPEN
Slide 20: OTC & Nutrition
Dr. Morepen® OTC & NUTRITION
Slide 21: Gross Revenue
GROSS REVENUE 28% CAGR Rs. in crores 125 ^23% 100 106 CAGR 11 % 86 30 75 65 28.18 50 23.07 up 37% from 49 20 20.61 pre-covid level 25 15.04 10 0 FY'20 FY'21 FY'22 H1'23 0 Annual performance Q2'FY20 Q2'FY21 Q2'FY22 Q2'FY23 Q2'FY23 performance JlOREPEN
Slide 22: Brand Portfolio
BRAND PORTFOLIO an established national household brand with extensive reach and trust 36% CAGR Rs. in crores ^36% 750 685 CAGR 18% 500 504 OTC 200 7.9% 192.24 371 Rx 150 157.16 307 30.7% 250 146.84 up 65% from pre-covid level 100 95.26 0 50 FY'20 FY'21 FY'22 H1'23 Devices 61.4% 0 Annual performance
Slide 23: Financial Highlights & Ratios
FINANCIAL highlights & ratios
Slide 24: Revenue Highlights (Q2)
CONSOLIDATED REVENUE HIGHLIGHTS (Q2) Rs. in crores net revenue EBIDTA PROFIT AFTER TAX 500 50 40 37.36 400 40 44.88 398.17 399.19 403.85 30 371.46 300 30 34.81 303.31 29.35 20 21.52 200 20 21.85 15.81 15.46 10 12.32 100 10 5.62 0 0 0 Q2'FY22 Q3'FY22 Q4'FY22 Q1'FY23 Q2'FY23 Q2'FY22 Q3'FY22 Q4'FY22 Q1
Slide 25: Thank you
Thank you love heals
Morepen Laboratories — Q2 FY2023 Earnings Presentation on 6ix